ALTSTATION.IO

Danaher Corporation (DHR) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$215.77

Change

+0.01%

Market Cap

$152.53B

Avg Volume

3.7M

Company Overview

Danaher Corporation designs and manufactures a broad range of products primarily for the healthcare sector, focusing on diagnostics and research. Their offerings include medical instruments, lab equipment, and consumables that support critical processes in hospitals, research labs, and biopharmaceutical companies. Customers span the spectrum from healthcare providers to industrial clients, all requiring high-quality tools and services for diagnostics, life sciences, and biotechnology applications.

Danaher is a market leader, consistently outperforming its competitors in innovation and scalability. Its comprehensive portfolio, which includes well-known brands like Beckman Coulter and Leica Microsystems, provides them with a significant edge, particularly in fast-growing areas like genomic medicine and precision diagnostics. However, the landscape is competitive, with other heavyweights like Thermo Fisher Scientific and Abbott Laboratories posing ongoing challenges. The ongoing consolidation in healthcare and the push towards personalized medicine could affect their market position if not navigated carefully.

Currently, Danaher is in a growth phase, driven by strong demand across all segments, particularly in Life Sciences and Diagnostics. Recent milestones include successful integration of acquisitions, which have bolstered their technology offerings and customer base. They are also pivoting towards more advanced automation solutions, aiming to enhance lab efficiency. This strategic direction signals an intent to capitalize on the increasing emphasis on automation and rapid diagnostics in the healthcare industry.

Key Financials

Market Cap

$152.53B

Revenue

$24.57B

EBITDA

$7.14B

Gross Margin

59.1%

Profit Margin

14.7%

Revenue Growth

4.6%

Total Cash

$4.62B

Total Debt

$18.42B

Free Cash Flow

$4.32B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

42.90

Forward P/E

23.66

Beta

0.96

52-Week High

$242.80

52-Week Low

$171.00

EPS

$5.03

50-Day Avg

$229.60

200-Day Avg

$208.71

Price/Book

2.90

Technical Analysis

The 52-week trend for Danaher Corporation (DHR) exhibits a moderate upward trajectory, with a current price of $215.77 reflecting a 7.1% increase over the period. Key support is seen around $200, which has held during multiple declines, while resistance appears near $220, where price retraced in recent months. A notable price pattern is the series of higher lows along with occasional consolidation phases, indicating a bullish sentiment despite periods of volatility. In recent weeks, momentum has weakened, with price dipping below the green trend line suggesting potential bearish pressure. Currently, the stock is slightly below the recent high near $216.61 and remains within a 52-week range that shows signs of struggle to push through the resistance zone, implying caution for potential long positions.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Danaher Corporation (DHR) stock from the past week (January 31 – February 7, 2026):

Market Update

### Danaher Beats Q4 2025 Earnings and Revenue Estimates, Provides Strong 2026 Guidance
Danaher Corporation announced its fourth-quarter and full-year 2025 results on January 28, 2026, surpassing Wall Street’s expectations with an adjusted earnings per share (EPS) of $2.23 against a forecast of $2.14, and revenue of $6.84 billion, slightly above the $6.79 billion estimate. The company also issued

Market Update

### Mixed Analyst Sentiment Following Earnings Report
Following the earnings release, Danaher received varied but generally positive analyst commentary. While JPMorgan raised its price target to $275 and maintained an overweight rating, Goldman Sachs trimmed its target slightly to $265 but kept a buy rating. Overall, the consensus rating from analysts remains a “Buy,” with MarketBeat reporting an

Market Sentiment and Analyst Recommendations

Bull Case

Danaher just delivered a beat on both earnings and revenue with adjusted EPS of $2.23 versus $2.14 expected, and management guided 2026 EPS between $8.35-$8.50, which sits above street consensus. The bioprocessing and diagnostics segments are firing on all cylinders with resilient demand, and Cytiva alone launched over 20 new products in 2025 across the biologics workflow. At a P/E of 42.90, the valuation is steep, but 22 analysts maintain a strong buy rating with an average target of $264.86, implying 22.7% upside from current levels. The company’s $4.62 billion cash position and manageable debt-to-equity ratio give it flexibility for M&A or shareholder returns. JPMorgan’s recent $275 target and the stock’s 7.1% gain over 52 weeks show institutional conviction despite recent weakness. The real driver here is recurring revenue from consumables in bioprocessing, which is sticky and growing faster than the overall 4.6% revenue growth rate suggests.

Bear Case

The stock dropped 6.84% in pre-market after beating earnings, which tells you the market doesn’t believe in the narrative anymore. A 42.90 P/E multiple is expensive for a company guiding only 3%-6% core revenue growth in 2026, and that’s not enough margin of safety if guidance misses. The debt load of $18.42 billion against $4.62 billion in cash leaves limited room for error, especially if bioprocessing demand softens. Recent momentum has weakened with the price dipping below the trend line, and the stock is struggling to break through the $220 resistance level, suggesting institutional buyers are taking profits. One analyst downgraded the stock citing that conservative guidance might understate EPS growth, which is code for “management isn’t being aggressive enough,” a red flag for execution. The 2.2% drop over the past week despite a beat shows the market is rotating away from high-multiple healthcare names into cheaper sectors.

What to Watch

Track Q1 2026 results in late April for actual execution against the 3%-6% growth guidance, especially bioprocessing segment margins and consumables revenue trends. Monitor whether the stock can break through and hold the $220-$225 resistance zone; failure to do so signals further downside to the $200 support level. Watch for any M&A announcements or capital allocation decisions, as the company has $4.62 billion in dry powder and a history of bolt-on acquisitions. Pay attention to competitive pressure from Sartorius and other bioprocessing rivals, particularly pricing power in consumables which is the margin driver. The analyst target range spreads from $220 to $310, which is too wide; convergence above $260 would validate the bull thesis, while a cluster below $240 suggests institutional money is exiting. Finally, monitor macro indicators on biopharma R&D spending and FDA drug approvals, since those directly impact bioprocessing consumables demand.

Analyst Consensus

STRONG BUY

Based on 22 analyst opinions

Low Target

$220.00

Mean Target

$264.86

High Target

$310.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

60,000

Earnings & Dividends

Next Earnings

Apr 21, 2026

EPS (Trailing)

$5.03

Dividend Yield

59.0%

Payout Ratio

25.4%

Frequently Asked Questions

Is DHR a good stock to buy?

Yes, Danaher Corporation (DHR) has an analyst recommendation of STRONG BUY with a target price of $264.86. Its current price of $215.77 represents strong upside potential.

What is DHR’s price target?

The current price target for Danaher stock is $264.86, according to analyst estimates. This suggests a potential increase of about 22.7% from its current trading price.

Does DHR pay a dividend?

Yes, Danaher has a dividend yield of 59.0%. This high yield indicates a strong commitment to returning value to shareholders, which can be appealing for income-focused investors.

What is Danaher’s P/E ratio?

Danaher has a P/E ratio of 42.90 and a forward P/E ratio of 23.66. While the current P/E is high, the lower forward P/E suggests that analysts expect earnings growth in the near term.

What was DHR’s 52-week range?

Danaher’s 52-week range is between $171.00 and $242.80. This range reflects the stock’s volatility and provides context for its current price relative to its performance over the past year.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.